The obesity drug liraglutide cut migraine days in half in a small trial, though more research is needed to exclude the placebo effect, researchers said.

Patients with migraine with aura show reduced migraine symptoms, less rescue medication use, and more sustained pain relief ...

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating ...

Atogepant 60 mg once daily leads to meaningful weight loss in patients with overweight or obesity receiving preventive ...

People with unresponsive chronic migraine and obesity experienced substantial relief after they started taking a GLP-1 drug, ...

Patients with migraine discontinued treatment less often with atogepant and experienced a greater reduction in mean monthly migraine days compared with topiramate, according to topline results from a ...

MR is associated with better treatment response than gepants in patients with migraine who previously had an inadequate response to gepants.

Liraglutide, a medication commonly used to treat diabetes, has shown promising results in reducing chronic migraine in ...

A recent study suggests that liraglutide, a drug similar to Ozempic, may reduce migraine frequency in obese individuals with ...

Migraine treatment with topiramate is linked to lower risks of end-stage kidney disease (ESKD), death, and ventricular arrhythmia/cardiac arrest, an investigator reported at the 62 nd European Renal ...

Already a household name in diabetes and weight management, Ozempic (semaglutide) may soon find another surprising role — as ...

Claire Szymanski woke one morning with what she thought was a "shocking" headache and four years on the pain has not stopped.